イスラエル - 英語 - Ministry of Health

glaxo smith kline (israel) ltd - diphtheria toxoid 30 iu / 0.5 ml; filamentous haemogglutinin (fha) 25 mcg / 0.5 ml - powder and suspension for suspension for injection - tetanus toxoid, combinations with diphtheria toxoid - active immunisation of all infants from the age of 2 months to 7 years of age against diptheria, tetanus, pertussis (dtp) and hib.

アイルランド - 英語 - HPRA (Health Products Regulatory Authority)

glaxosmithkline (ireland) limited - diphtheria toxoid tetanus toxoid pertussis vaccine filamentous haemagglutinin (fha) pertactin polio virus type 1 inactivated polio virus type 2 inactivated polio virus type 3 inactivated haemophilus influenzae type b capsular polysaccharide (prp) and tetanus toxoid - powder for suspension for injection

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - pertussis filamentous haemagglutinin; pertactin; pertussis toxoid; tetanus toxoid; poliovirus; diphtheria toxoid -

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - pertussis filamentous haemagglutinin; poliovirus; tetanus toxoid; pertactin; pertussis toxoid; hepatitis b surface antigen recombinant; polyribose ribitol phosphate - haemophilus influenzae type b; diphtheria toxoid -

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

pertactin; diphtheria toxoid; pertussis toxoid; poliovirus; tetanus toxoid; pertussis filamentous haemagglutinin -

アメリカ合衆国 - 英語 - NLM (National Library of Medicine)

a-s medication solutions - clostridium tetani toxoid antigen (formaldehyde inactivated) (unii: k3w1n8yp13) (clostridium tetani toxoid antigen (formaldehyde inactivated) - unii:k3w1n8yp13), corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) (unii: irh51qn26h) (corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) - unii:irh51qn26h), bordetella pertussis toxoid antigen (formaldehyde, glutaraldehyde inactivated) (unii: qsn5xo8zsu) (bordetella pertussis toxoid antigen (formaldehyde, glutaraldehyde in - infanrix is indicated for active immunization against diphtheria, tetanus, and pertussis as a 5-dose series in infants and children aged 6 weeks through 6 years (prior to the 7th birthday). severe allergic reaction (e.g., anaphylaxis) after a previous dose of any diphtheria toxoid-, tetanus toxoid-, or pertussis-containing vaccine, or to any component of infanrix is a contraindication [see description (11)] . because of the uncertainty as to which component of the vaccine might be responsible, no further vaccination with any of these components should be given. alternatively, such individuals may be referred to an allergist for evaluation if immunization with any of these components is being considered. encephalopathy (e.g., coma, decreased level of consciousness, prolonged seizures) within 7 days of administration of a previous dose of a pertussis-containing vaccine that is not attributable to another identifiable cause is a contraindication to administration of any pertussis-containing vaccine, including in

ベルギー - 英語 - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

glaxosmithkline biologicals sa-nv - conjugate of haemophilus influenzae type b capsular polysaccharide and tetanus toxoid 30 µg - 50 µg; bordetella pertussis filamentous hemagglutinin (fha) 25 µg/dose; diphtheria toxoid (dt) >= 30 iu/dose; bordetella pertussis pertactin 8 µg/dose; tetanus toxoid >= 40 iu/dose; bordetella pertussis toxoid (pt) 25 µg/dose - powder and suspension for suspension for injection - diphteria antigen, adsorbed; haemophilus influenzae type b polysaccharides, conjugated to tetanus toxoid; tetanus toxoid adsorbed; bordetella pertussis antigen, proteins - hemophilus influenzae b, combinations with toxoids

ベルギー - 英語 - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

glaxosmithkline biologicals sa-nv - poliovirus type 2 (inactivated) 8 d-antigen u/1 dose; poliovirus type 3 (inactivated) 32 d-antigen u/1 dose; poliovirus type 1 (inactivated) 40 d-antigen u/1 dose; bordetella pertussis pertactin 8 µg/dose; tetanus toxoid >= 40 iu/dose; bordetella pertussis filamentous hemagglutinin (fha) 25 µg/dose; bordetella pertussis toxoid (pt) 25 µg/dose; diphtheria toxoid (dt) >= 30 iu/dose; conjugate of haemophilus influenzae type b capsular polysaccharide and tetanus toxoid - powder and solvent for suspension for injection - diphteria antigen, adsorbed; haemophilus influenzae type b polysaccharides, conjugated to tetanus toxoid; poliomyelitis virus; tetanus toxoid adsorbed; bordetella pertussis antigen, proteins - diphtheria-hemophilus influenzae b-pertussis-poliomyelitis-tetanus

ベルギー - 英語 - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

glaxosmithkline biologicals sa-nv - conjugate of haemophilus influenzae type b capsular polysaccharide and tetanus toxoid 30 µg - 50 µg; bordetella pertussis filamentous hemagglutinin (fha) 25 µg/dose; diphtheria toxoid (dt) >= 30 iu/dose; bordetella pertussis pertactin 8 µg/dose; tetanus toxoid >= 40 iu/dose; bordetella pertussis toxoid (pt) 25 µg/dose - powder and suspension for suspension for injection - hemophilus influenzae b, combinations with toxoids

ニュージーランド - 英語 - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - meningococcal oligosaccharide - group c 10ug (conjugated with 5 mcg diphtheria crm 197 protein);   - suspension for injection - 0.5 ml - active: meningococcal oligosaccharide - group c 10ug (conjugated with 5 mcg diphtheria crm 197 protein)   excipient: aluminium phosphate sodium chloride water for injection - active immunisation of children from 6 weeks of age, adolescents and adults for the prevention of invasive disease caused by neisseria meningitidis serogroup c.